What is the prevalence of Peyronies Disease?

TL;DR: Peyronie’s disease is estimated to affect between 0.5% and 13% of the male population, with prevalence rates varying significantly based on the study methodology and the age of the cohort. While often considered underdiagnosed, Peyronie’s disease is most commonly identified in men between the ages of 40 and 70, with very few cases reported in pediatric populations.

What is the estimated prevalence of Peyronie’s disease?

Determining the exact prevalence of Peyronie’s disease is challenging because many men do not seek medical attention due to the sensitive nature of the condition or the assumption that symptoms are a normal part of aging. Clinical literature, including data from the NIH GARD, suggests a prevalence range of 0.5% to 13%. This wide variance exists because some studies rely on self-reported symptoms, while others rely on clinical physical examinations. In the DiseaseMaps.org community, we have seen 8 individuals connect to share their personal experiences with Peyronie’s disease, highlighting that while it may not be considered "ultra-rare," it remains a condition that often leads to isolation for those affected.

Does Peyronie’s disease affect males and females differently?

Peyronie’s disease is a condition that specifically affects the male anatomy, involving the development of fibrous scar tissue (plaques) within the tunica albuginea of the penis. Because the pathology is tied to the structure of the penis, it is not a condition that affects females. While there are analogous connective tissue disorders, Peyronie’s disease is clinically defined by its impact on male sexual health and penile curvature.

What is the typical age of onset for Peyronie’s disease?

Peyronie’s disease is predominantly a condition of adulthood, with most diagnoses occurring between the ages of 40 and 70. The average age of onset is typically cited around 50 years. While it is extremely rare in pediatric populations, cases in younger men have been documented, often associated with trauma or underlying genetic predispositions to connective tissue disorders. Understanding the age distribution is vital for clinicians to differentiate Peyronie’s disease from other causes of penile curvature or pain.

Why is accurate data on Peyronie’s disease difficult to obtain?

Several factors contribute to the difficulty in establishing precise epidemiological data for Peyronie’s disease:

• Social Stigma: Many patients delay seeking care due to embarrassment, leading to a significant number of "silent" cases.


• Underdiagnosis: Physicians may not always perform a thorough physical exam for penile curvature unless the patient explicitly voices the concern.


• Varied Definitions: Differences in how "clinically significant" curvature is defined across global studies lead to inconsistent reporting.


• Misdiagnosis: Early-stage symptoms, which may include pain without visible deformity, are sometimes mistaken for other inflammatory conditions.

Are there geographic or ethnic variations?

Current medical literature does not strongly suggest that Peyronie’s disease is restricted to specific geographic regions or ethnic groups. However, because access to urological care varies globally, prevalence statistics are often skewed toward countries with higher rates of healthcare utilization and more robust medical reporting systems. Further research is needed to determine if environmental or genetic factors influence the incidence of the disease across diverse populations.

Next steps

• Consult a board-certified urologist who specializes in sexual medicine or andrology to discuss your specific symptoms.


• Keep a symptom diary tracking pain levels and the degree of curvature to assist your physician in diagnosis.


• Join the DiseaseMaps.org community to read shared experiences from others living with Peyronie’s disease.


• Ask your doctor about the latest clinical trials or non-surgical treatment options currently being studied for plaque reduction.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Peyronie’s disease overview.


• Orphanet: Database of rare diseases and orphan drugs.


• PubMed/NCBI: Systematic reviews on the prevalence and pathophysiology of Peyronie’s disease.


• International Society for Sexual Medicine (ISSM): Clinical guidelines for the management of Peyronie’s disease.